Rimonabant Acomplia works by blocking the CB1 receptor, one of two receptors found in a newly described physiological system called the Endocannabinoid System (EC System) , believed to play a critical role in the regulation of food intake and energy expenditure. The receptors are present on the surfaces of many cells throughout the body, including fat cells — which are involved in lipid and glucose metabolism — and those in the hypothalamus, the brain region that is thought to determine appetite.
